{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:20Z","timestamp":1790286920046,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009780","name":"Char and Chuck Fowler Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10147-019-01490-2","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T13:02:23Z","timestamp":1563454943000},"page":"1171-1181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Immune checkpoint inhibitor-induced sarcoidosis-like granulomas"],"prefix":"10.1007","volume":"24","author":[{"given":"Pooja H.","family":"Rambhia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey F.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley N.","family":"Feneran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan A.","family":"Kazakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kord","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Koon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6080-0980","authenticated-orcid":false,"given":"Meg R.","family":"Gerstenblith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"21","key":"1490_CR1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028","journal-title":"N Engl J Med"},{"issue":"2","key":"1490_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41416-018-0131-9","volume":"119","author":"R Mehra","year":"2018","unstructured":"Mehra R, Seiwert TY, Gupta S et al (2018) Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer 119(2):153\u2013159","journal-title":"Br J Cancer"},{"issue":"19","key":"1490_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813","journal-title":"N Engl J Med"},{"issue":"19","key":"1490_CR4","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein GJ, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375(19):1856\u20131867","journal-title":"N Engl J Med"},{"issue":"14","key":"1490_CR5","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.jmb.2018.05.030","volume":"430","author":"N Borcherding","year":"2018","unstructured":"Borcherding N, Kolb R, Gullicksrud J et al (2018) Keeping tumors in check: a mechanistic review of clinical response and resistance to immune checkpoint blockade in cancer. J Mol Biol 430(14):2014\u20132029","journal-title":"J Mol Biol"},{"issue":"127","key":"1490_CR6","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD et al (2012) Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4(127):127ra37","journal-title":"Sci Transl Med"},{"issue":"9","key":"1490_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/labinvest.2017.64","volume":"97","author":"GJ Kaunitz","year":"2017","unstructured":"Kaunitz GJ, Cottrell TR, Lilo M et al (2017) Melanoma subtypes demonstrate distinct PD-L1 expression profiles. Lab Investig 97(9):1063\u20131071","journal-title":"Lab Investig"},{"issue":"12","key":"1490_CR8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/ni.2762","volume":"14","author":"T Okazaki","year":"2013","unstructured":"Okazaki T, Chikuma S, Iwai Y et al (2013) A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14(12):1212\u20131218","journal-title":"Nat Immunol"},{"issue":"26","key":"1490_CR9","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532","journal-title":"N Engl J Med"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","volume":"82","author":"S Le Burel","year":"2017","unstructured":"Le Burel S, Champiat S, Mateus C et al (2017) Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer 82:34\u201344","journal-title":"Eur J Cancer"},{"issue":"1","key":"1490_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000161122","volume":"218","author":"A Eckert","year":"2009","unstructured":"Eckert A, Schoeffler A, Dalle S et al (2009) Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 218(1):69\u201370","journal-title":"Dermatology"},{"issue":"17","key":"1490_CR12","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","volume":"30","author":"G Berthod","year":"2012","unstructured":"Berthod G, Lazor R, Letovanec I et al (2012) Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 30(17):e156\u2013e159","journal-title":"J Clin Oncol"},{"issue":"5","key":"1490_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","volume":"13","author":"AJM van den Eertwegh","year":"2012","unstructured":"van den Eertwegh AJM, Versluis J, van den Berg HP et al (2012) Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 13(5):509\u2013517","journal-title":"Lancet Oncol"},{"issue":"2","key":"1490_CR14","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1200\/JCO.2011.37.9693","volume":"30","author":"WV Vogel","year":"2012","unstructured":"Vogel WV, Guislain A, Kvistborg P et al (2012) Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. J Clin Oncol 30(2):e7\u2013e10","journal-title":"J Clin Oncol"},{"issue":"4","key":"1490_CR15","first-page":"1355","volume":"32","author":"S Wilgenhof","year":"2012","unstructured":"Wilgenhof S, Morlion V, Seghers AC et al (2012) Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res 32(4):1355\u20131359","journal-title":"Anticancer Res"},{"issue":"5","key":"1490_CR16","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","volume":"69","author":"RB Reule","year":"2013","unstructured":"Reule RB, North JP (2013) Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol 69(5):e272\u2013e273","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1490_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1183\/09031936.00107912","volume":"41","author":"C Tissot","year":"2013","unstructured":"Tissot C, Carsin A, Freymond N et al (2013) Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. Eur Respir J 41(1):246\u2013247","journal-title":"Eur Respir J"},{"issue":"8","key":"1490_CR18","doi-asserted-by":"publisher","first-page":"e954506","DOI":"10.4161\/21624011.2014.954506","volume":"3","author":"R Andersen","year":"2014","unstructured":"Andersen R, Norgaard P, Al-Jailawi MKM et al (2014) Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology 3(8):e954506","journal-title":"Oncoimmunology"},{"issue":"6","key":"1490_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000362614","volume":"37","author":"KP Murphy","year":"2014","unstructured":"Murphy KP, Kennedy MP, Barry JE et al (2014) New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 37(6):351\u2013353","journal-title":"Oncol Res Treat"},{"issue":"8","key":"1490_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1177\/1078155216667635","volume":"23","author":"B Firwana","year":"2017","unstructured":"Firwana B, Ravilla R, Raval M et al (2017) Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract 23(8):620\u2013624","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"1490_CR21","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/dth.12380","volume":"29","author":"L Martinez Leborans","year":"2016","unstructured":"Martinez Leborans L, Esteve Martinez A, Victoria Martinez AM et al (2016) Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy. Dermatol Ther 29(5):306\u2013308","journal-title":"Dermatol Ther"},{"issue":"4","key":"1490_CR22","doi-asserted-by":"publisher","first-page":"e1068","DOI":"10.1097\/MJT.0000000000000266","volume":"23","author":"A Toumeh","year":"2016","unstructured":"Toumeh A, Sakhi R, Shah S et al (2016) Ipilimumab-induced granulomatous disease occurring simultaneously with disease progression in a patient with metastatic melanoma. Am J Ther 23(4):e1068\u2013e1071","journal-title":"Am J Ther"},{"issue":"3","key":"1490_CR23","doi-asserted-by":"publisher","first-page":"e379","DOI":"10.1097\/MJT.0000000000000545","volume":"25","author":"S Nandavaram","year":"2018","unstructured":"Nandavaram S, Nadkarni A (2018) Ipilimumab-induced sarcoidosis and thyroiditis. Am J Ther 25(3):e379\u2013e380","journal-title":"Am J Ther"},{"issue":"4","key":"1490_CR24","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jdcr.2016.06.004","volume":"2","author":"J Cotliar","year":"2016","unstructured":"Cotliar J, Querfeld C, Boswell WJ et al (2016) Pembrolizumab-associated sarcoidosis. JAAD Case Rep 2(4):290\u2013293","journal-title":"JAAD Case Rep"},{"issue":"6","key":"1490_CR25","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1093\/annonc\/mdw125","volume":"27","author":"S Cousin","year":"2016","unstructured":"Cousin S, Toulmonde M, Kind M et al (2016) Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol Off J Eur Soc Med Oncol 27(6):1178\u20131179","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"1490_CR26","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.chest.2015.10.082","volume":"149","author":"F-X Danlos","year":"2016","unstructured":"Danlos F-X, Pages C, Baroudjian B et al (2016) Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest 149(5):e133\u2013e136","journal-title":"Chest"},{"issue":"4","key":"1490_CR27","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/bjd.14808","volume":"176","author":"H Montaudie","year":"2017","unstructured":"Montaudie H, Pradelli J, Passeron T et al (2017) Pulmonary sarcoid-like granulomatosis induced by nivolumab. Br J Dermatol 176(4):1060\u20131063","journal-title":"Br J Dermatol"},{"issue":"3","key":"1490_CR28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jdcr.2017.02.015","volume":"3","author":"MR Birnbaum","year":"2017","unstructured":"Birnbaum MR, Ma MW, Fleisig S et al (2017) Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep 3(3):208\u2013211","journal-title":"JAAD Case Rep"},{"issue":"7","key":"1490_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamadermatol.2017.0581","volume":"153","author":"S Burillo-Martinez","year":"2017","unstructured":"Burillo-Martinez S, Morales-Raya C, Prieto-Barrios M et al (2017) Pembrolizumab-induced extensive panniculitis and nevus regression: two novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum. JAMA Dermatol 153(7):721\u2013722","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1490_CR30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1159\/000484596","volume":"10","author":"G Fakhri","year":"2017","unstructured":"Fakhri G, Akel R, Salem Z et al (2017) Pulmonary sarcoidosis activation following neoadjuvant pembrolizumab plus chemotherapy combination therapy in a patient with non-small cell lung cancer: a case report. Case Rep Oncol 10(3):1070\u20131075","journal-title":"Case Rep Oncol"},{"issue":"6","key":"1490_CR31","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1159\/000480155","volume":"94","author":"S Lainez","year":"2017","unstructured":"Lainez S, Tissot C, Cottier M et al (2017) EBUS-TBNA can distinguish sarcoid-like side effect of nivolumab treatment from tumor progression in non-small cell lung cancer. Respiration 94(6):518\u2013521","journal-title":"Respiration"},{"key":"1490_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ajoc.2016.12.014","volume":"5","author":"Q-K Lise","year":"2017","unstructured":"Lise Q-K, Audrey A-G (2017) Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab. Am J Ophthalmol Case Rep 5:92\u201393","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"9","key":"1490_CR33","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/1756-185X.13076","volume":"20","author":"AJ Lomax","year":"2017","unstructured":"Lomax AJ, McGuire HM, McNeil C et al (2017) Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis 20(9):1277\u20131285","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"1490_CR34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1097\/RLU.0000000000001758","volume":"42","author":"M Zhang","year":"2017","unstructured":"Zhang M, Schembri G (2017) Nivolumab-induced development of pulmonary sarcoidosis in renal cell carcinoma. Clin Nucl Med 42(9):728\u2013729","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1490_CR35","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","volume":"28","author":"F Dimitriou","year":"2018","unstructured":"Dimitriou F, Frauchiger AL, Urosevic-Maiwald M et al (2018) Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 28(3):230\u2013236","journal-title":"Melanoma Res."},{"key":"1490_CR36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/1203475418776934","volume":"22","author":"A Laroche","year":"2018","unstructured":"Laroche A, Alarcon Chinchilla E, Bourgeault E et al (2018) Erythema nodosum as the initial presentation of nivolumab-induced sarcoidosis-like reaction. J Cutan Med Surg 22:627\u2013629","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"1490_CR37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0715","volume":"6","author":"M Nishino","year":"2018","unstructured":"Nishino M, Sholl LM, Awad MM et al (2018) Sarcoid-like granulomatosis of the lung related to immune-checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event. Cancer Immunol Res 6(6):630\u2013635","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"1490_CR38","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1159\/000492383","volume":"11","author":"S Noguchi","year":"2018","unstructured":"Noguchi S, Kawachi H, Yoshida H et al (2018) Sarcoid-like granulomatosis induced by nivolumab treatment in a lung cancer patient. Case Rep Oncol 11(2):562\u2013566","journal-title":"Case Rep Oncol"},{"key":"1490_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/cup.13307","volume":"45","author":"RJ Smith","year":"2018","unstructured":"Smith RJ, Mitchell TC, Chu EY (2018) Pembrolizumab-induced sarcoidal infusion site reaction. J Cutan Pathol 45:727\u2013729","journal-title":"J Cutan Pathol"},{"issue":"1","key":"1490_CR40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","volume":"6","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Nelson KC, Diab A et al (2018) Granulomatous\/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 6(1):14","journal-title":"J Immunother Cancer"},{"key":"1490_CR41","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","volume":"154","author":"LL Wang","year":"2018","unstructured":"Wang LL, Patel G, Chiesa-Fuxench ZC et al (2018) Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol 154:1057\u20131061","journal-title":"JAMA Dermatol"},{"issue":"7","key":"1490_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/DAD.0000000000001066","volume":"40","author":"R Woodbeck","year":"2018","unstructured":"Woodbeck R, Metelitsa AI, Naert KA (2018) Granulomatous tumoral melanosis associated with pembrolizumab therapy: a mimicker of disease progression in metastatic melanoma. Am J Dermatopathol 40(7):523\u2013526","journal-title":"Am J Dermatopathol"},{"key":"1490_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","volume":"4","author":"VH Koelzer","year":"2016","unstructured":"Koelzer VH, Rothschild SI, Zihler D et al (2016) Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 4:13","journal-title":"J Immunother Cancer"},{"key":"1490_CR44","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","volume":"4","author":"JE Reuss","year":"2016","unstructured":"Reuss JE, Kunk PR, Stowman AM et al (2016) Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report and review of the literature. J Immunother Cancer 4:94","journal-title":"J Immunother Cancer"},{"issue":"3","key":"1490_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jdcr.2016.05.002","volume":"2","author":"KC Suozzi","year":"2016","unstructured":"Suozzi KC, Stahl M, Ko CJ et al (2016) Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep 2(3):264\u2013268","journal-title":"JAAD Case Rep"},{"issue":"8","key":"1490_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/CJI.0000000000000181","volume":"40","author":"SB Reddy","year":"2017","unstructured":"Reddy SB, Possick JD, Kluger HM et al (2017) Sarcoidosis following anti-PD-1 and anti-CTLA-4 therapy for metastatic melanoma. J Immunother 40(8):307\u2013311","journal-title":"J Immunother"},{"issue":"2","key":"1490_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000491599","volume":"11","author":"AM Dunn-Pirio","year":"2018","unstructured":"Dunn-Pirio AM, Shah S, Eckstein C (2018) Neurosarcoidosis following immune checkpoint inhibition. Case Rep Oncol 11(2):521\u2013526","journal-title":"Case Rep Oncol"},{"issue":"1","key":"1490_CR48","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40425-018-0390-2","volume":"6","author":"I Tan","year":"2018","unstructured":"Tan I, Malinzak M, Salama AKS (2018) Delayed onset of neurosarcoidosis after concurrent ipilimumab\/nivolumab therapy. J Immunother Cancer 6(1):77","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1490_CR49","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.revmed.2017.11.008","volume":"39","author":"N Yatim","year":"2018","unstructured":"Yatim N, Mateus C, Charles P (2018) Sarcoidosis post-anti-PD-1 therapy, mimicking relapse of metastatic melanoma in a patient undergoing complete remission. La Rev Med Interne 39(2):130\u2013133","journal-title":"La Rev Med Interne"},{"issue":"2","key":"1490_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/RLU.0000000000002408","volume":"44","author":"Y Lu","year":"2019","unstructured":"Lu Y (2019) FDG PET\/CT course of pembrolizumab-associated multiorgan sarcoidosis. Clin Nucl Med. 44(2):167\u2013168","journal-title":"Clin Nucl Med."},{"issue":"8","key":"1490_CR51","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrrheum.2011.93","volume":"7","author":"ES Chen","year":"2011","unstructured":"Chen ES, Moller DR (2011) Sarcoidosis\u2014scientific progress and clinical challenges. Nat Rev Rheumatol 7(8):457\u2013467","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1490_CR52","first-page":"334","volume":"15","author":"E Mortaz","year":"2016","unstructured":"Mortaz E, Rezayat F, Amani D et al (2016) The roles of T helper 1, T helper 17 and regulatory T cells in the pathogenesis of sarcoidosis. Iran J Allergy Asthma Immunol 15(4):334\u2013339","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"1490_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1479-5876-7-35","volume":"7","author":"E von Euw","year":"2009","unstructured":"von Euw E, Chodon T, Attar N et al (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7:35","journal-title":"J Transl Med"},{"issue":"4","key":"1490_CR54","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1002\/eji.201444778","volume":"45","author":"JW McAlees","year":"2015","unstructured":"McAlees JW, Lajoie S, Dienger K et al (2015) Differential control of CD4(+) T-cell subsets by the PD-1\/PD-L1 axis in a mouse model of allergic asthma. Eur J Immunol 45(4):1019\u20131029","journal-title":"Eur J Immunol"},{"issue":"7","key":"1490_CR55","doi-asserted-by":"publisher","first-page":"e0160221","DOI":"10.1371\/journal.pone.0160221","volume":"11","author":"N Abdel-Wahab","year":"2016","unstructured":"Abdel-Wahab N, Shah M, Suarez-Almazor ME (2016) Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. PLoS ONE 11(7):e0160221","journal-title":"PLoS ONE"},{"issue":"7614","key":"1490_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature18945","volume":"536","author":"EME Verdegaal","year":"2016","unstructured":"Verdegaal EME, de Miranda NFCC, Visser M et al (2016) Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 536(7614):91\u201395","journal-title":"Nature"},{"issue":"5","key":"1490_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMcibr1613793","volume":"376","author":"VN Kristensen","year":"2017","unstructured":"Kristensen VN (2017) The Antigenicity of the tumor cell\u2014context matters. N Engl J Med 376(5):491\u2013493","journal-title":"N Engl J Med"},{"key":"1490_CR58","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fonc.2018.00270","volume":"8","author":"S Kitano","year":"2018","unstructured":"Kitano S, Nakayama T, Yamashita M (2018) Biomarkers for immune checkpoint inhibitors in melanoma. Front Oncol 8:270","journal-title":"Front Oncol"},{"issue":"1","key":"1490_CR59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000213245","volume":"219","author":"P Seve","year":"2009","unstructured":"Seve P, Schott AM, Pavic M et al (2009) Sarcoidosis and melanoma: a referral center study of 1,199 cases. Dermatology 219(1):25\u201331","journal-title":"Dermatology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01490-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01490-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01490-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T23:31:03Z","timestamp":1594942263000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01490-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01490-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]},"assertion":[{"value":"21 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Author PHR declares that she has no conflict of interest. Author BR declares that she has no conflict of interest. Author JFS declares that he has no conflict of interest. Author ANF declares that she has no conflict of interest. Author JAK declares that he has no conflict of interest. Author KH declares that he has no conflict of interest. Author HK owns stock in Company BMS. Author MRG has received research grants from the Char and Chuck Fowler Family Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}